Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bristol-Myers Squibb Company stock in Canada | $61.31

Own Bristol-Myers Squibb Company shares in just a few minutes.

Bristol-Myers Squibb Company
NYSE: BMY - USD
DRUG MANUFACTURERS-GENERAL
$61.31
+ $0.08 ( + 0.13%)

Bristol-Myers Squibb Company is a drug manufacturers-general business based in the US. Bristol-Myers Squibb Company stocks (BMY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $61.23 – a decrease of 2.88% over the previous week. Bristol-Myers Squibb Company employs 30,250 staff and has a trailing 12-month revenue of around $44.4 billion.

How to buy Bristol-Myers Squibb Company stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BMY in this case.
  5. Research Bristol-Myers Squibb Company stocks. The platform should provide the latest information available.
  6. Buy your Bristol-Myers Squibb Company stocks. It's that simple.

Is it a good time to buy Bristol-Myers Squibb Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Bristol-Myers Squibb Company's stock price?

Since the stock market crash in March caused by coronavirus, Bristol-Myers Squibb Company's stock price has had significant negative movement.

Its last market close was $61.31, which is 6.58% down on its pre-crash value of $65.63 and 33.98% up on the lowest point reached during the March crash when the stocks fell as low as $45.76.

If you had bought $1,000 worth of Bristol-Myers Squibb Company stocks at the start of February 2020, those stocks would have been worth $729.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $964.41.

Bristol-Myers Squibb Company stock price

Use our graph to track the performance of BMY stocks over time.

Bristol-Myers Squibb Company stocks at a glance

Information last updated 2021-09-17.
Latest market close$61.31
52-week range$55.1871 - $69.75
50-day moving average $66.6574
200-day moving average $65.3036
Wall St. target price$80.24
Dividend yield $1.92 (3.14%)
Earnings per share (TTM) $-2.264

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.

An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Bristol-Myers Squibb Company price performance over time

Historical closes compared with the last close of $61.31

1 week (2021-09-09) -3.57%
1 month (2021-08-19) -10.51%
3 months (2021-06-18) -7.76%
6 months (2021-03-19) -2.22%
1 year (2020-09-18) 3.44%
2 years (2019-09-18) 22.96%
3 years (2018-09-18) -0.28%
5 years (2016-09-16) 10.27%

Is Bristol-Myers Squibb Company under- or over-valued?

Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bristol-Myers Squibb Company's PEG ratio

Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 14.5784. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Bristol-Myers Squibb Company's EBITDA

Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$18.8 billion.

The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.

Bristol-Myers Squibb Company financials

Revenue TTM USD$44.4 billion
Operating margin TTM 18.55%
Gross profit TTM USD$34 billion
Return on assets TTM 4.31%
Return on equity TTM -11.76%
Profit margin -11.44%
Book value $16.564
Market capitalisation USD$136.2 billion

TTM: trailing 12 months

How to short and sell Bristol-Myers Squibb Company stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "BMY.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 20.3 million Bristol-Myers Squibb Company stocks held short by investors – that's known as Bristol-Myers Squibb Company's "short interest". This figure is 7.2% down from 21.9 million last month.

There are a few different ways that this level of interest in shorting Bristol-Myers Squibb Company stocks can be evaluated.

Bristol-Myers Squibb Company's "short interest ratio" (SIR)

Bristol-Myers Squibb Company's "short interest ratio" (SIR) is the quantity of Bristol-Myers Squibb Company stocks currently shorted divided by the average quantity of Bristol-Myers Squibb Company stocks traded daily (recently around 6.9 million). Bristol-Myers Squibb Company's SIR currently stands at 2.94. In other words for every 100,000 Bristol-Myers Squibb Company stocks traded daily on the market, roughly 2940 stocks are currently held short.

However Bristol-Myers Squibb Company's short interest can also be evaluated against the total number of Bristol-Myers Squibb Company stocks, or, against the total number of tradable Bristol-Myers Squibb Company stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bristol-Myers Squibb Company's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Bristol-Myers Squibb Company stocks in existence, roughly 10 stocks are currently held short) or 0.0093% of the tradable stocks (for every 100,000 tradable Bristol-Myers Squibb Company stocks, roughly 9 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Bristol-Myers Squibb Company.

Find out more about how you can short Bristol-Myers Squibb Company stock.

Bristol-Myers Squibb Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Bristol-Myers Squibb Company's total ESG risk score

Total ESG risk: 29.16

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 01/01/2019) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Bristol-Myers Squibb Company's environmental score

Environmental score: 3.83/100

Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's social score

Social score: 18.82/100

Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Bristol-Myers Squibb Company's governance score

Governance score: 14.02/100

Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.

Total ESG score 29.16
Total ESG percentile 52.58
Environmental score 3.83
Environmental score percentile 4
Social score 18.82
Social score percentile 4
Governance score 14.02
Governance score percentile 4
Level of controversy 2

Bristol-Myers Squibb Company stock dividends

29%

Dividend payout ratio: 28.99% of net profits

Recently Bristol-Myers Squibb Company has paid out, on average, around 28.99% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.2% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 3.2% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $1.92 per share.

While Bristol-Myers Squibb Company's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb Company may be investing much of the rest of its net profits in future growth.

Bristol-Myers Squibb Company's most recent dividend payout was on 1 November 2021. The latest dividend was paid out to all shareholders who bought their stocks by 30 September 2021 (the "ex-dividend date").

Have Bristol-Myers Squibb Company stocks ever split?

Bristol-Myers Squibb Company stocks were split on a 1000000:95 basis on 7 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company stocks – just the quantity. However, indirectly, the new 100% lower stock price could have impacted the market appetite for Bristol-Myers Squibb Company stocks which in turn could have impacted Bristol-Myers Squibb Company's stock price.

Bristol-Myers Squibb Company stock price volatility

Over the last 12 months, Bristol-Myers Squibb Company's stocks have ranged in value from as little as $55.1871 up to $69.75. A popular way to gauge a stock's volatility is its "beta".

BMY.US volatility(beta: 0.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.5879. This would suggest that Bristol-Myers Squibb Company's stocks are less volatile than average (for this exchange).

Bristol-Myers Squibb Company overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site